Comparative Pharmacology
Head-to-head clinical analysis: IMPOYZ versus VIZZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPOYZ versus VIZZ.
IMPOYZ vs VIZZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IMPOYZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and attenuates the inflammatory cascade.
Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
100 mg orally twice daily
80 mg orally once daily
None Documented
None Documented
Terminal elimination half-life 6–8 hours in adults with normal renal function; prolonged to 15–30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 18-24 hours. Steady-state is reached within 4-5 days; accumulation may occur in renal impairment.
Primarily renal (70–80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal (15–20%) with minor hepatic metabolism.
Primarily hepatic metabolism with renal excretion of metabolites. Approximately 60% of a dose is excreted in urine as metabolites, 30% in feces, and <5% unchanged.
Category C
Category C
Unknown
Unknown